Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Improved therapeutic window in BRCA mutant tumors with antibody linked pyrrolobenzodiazepine dimers with and without PARP inhibition.

Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA.

Mol Cancer Ther. 2018 Oct 23. pii: molcanther.0314.2018. doi: 10.1158/1535-7163.MCT-18-0314. [Epub ahead of print]

PMID:
30352801
2.

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.

Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, Hardcastle N, Montgomery R, Vanneste B, Khoo V, Ruben J, Lau E, Hofman MS, De Abreu Lourenco R, Sridharan S, Brook NR, Martin J, Lawrentschuk N, Kron T, Foroudi F.

BMC Cancer. 2018 Oct 23;18(1):1030. doi: 10.1186/s12885-018-4916-2.

3.

Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.

Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, Ranade K.

Clin Cancer Res. 2018 Aug 9. doi: 10.1158/1078-0432.CCR-18-0386. [Epub ahead of print]

PMID:
30093454
4.

Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.

Streicher K, Sridhar S, Kuziora M, Morehouse CA, Higgs BW, Sebastian Y, Groves CJ, Pilataxi F, Brohawn PZ, Herbst R, Ranade K.

Arthritis Rheumatol. 2018 Jun 29. doi: 10.1002/art.40656. [Epub ahead of print]

PMID:
29956883
5.

Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method.

Tsiamis E, Millar J, Baxi S, Borg M, De Ieso P, Elsaleh H, Foroudi F, Higgs B, Holt T, Martin J, Moretti K, Pryor D, Skala M, Evans S.

Radiother Oncol. 2018 Aug;128(2):308-314. doi: 10.1016/j.radonc.2018.04.017. Epub 2018 May 9.

PMID:
29753551
6.

Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.

Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K.

Clin Cancer Res. 2018 Aug 15;24(16):3857-3866. doi: 10.1158/1078-0432.CCR-17-3451. Epub 2018 May 1.

PMID:
29716923
7.

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.

Zheng Y, Narwal R, Jin C, Baverel PG, Jin X, Gupta A, Ben Y, Wang B, Mukhopadhyay P, Higgs BW, Roskos L.

Clin Pharmacol Ther. 2018 Apr;103(4):643-652. doi: 10.1002/cpt.986. Epub 2018 Jan 17.

8.

High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease.

Higgs BW, Liu Y, Guo J, Sebastian Y, Morehouse C, Zhu W, Ren L, Liu M, Du Y, Yu G, Dong L, Hua H, Wei P, Wang Y, Wang Z, Yao Y, Li ZG.

Sci Rep. 2017 Dec 14;7(1):17567. doi: 10.1038/s41598-017-17602-9.

9.

Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.

Guo X, Higgs BW, Bay-Jensen AC, Wu Y, Karsdal MA, Kuziora M, Godwood A, Close D, Ryan PC, Roskos LK, White WI.

Rheumatology (Oxford). 2018 Jan 1;57(1):175-184. doi: 10.1093/rheumatology/kex383.

PMID:
29069507
10.

Synergistic immunosuppression and unintended consequences.

Sindhi R, Higgs BW, Venkataramanan R, Moritz ML.

Pediatr Transplant. 2017 Nov;21(7). doi: 10.1111/petr.13047. Epub 2017 Aug 21. No abstract available.

PMID:
28833989
11.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.

Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, Higgs BW, McCourt M, Jones H, Harper JA, Morrow M, Valge-Archer V, Stewart R, Dovedi SJ, Wilkinson RW.

Cancer Immunol Res. 2017 Jan;5(1):29-41. doi: 10.1158/2326-6066.CIR-16-0114. Epub 2016 Dec 6.

12.

Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma.

Ranganathan S, Ningappa M, Ashokkumar C, Higgs BW, Min J, Sun Q, Schmitt L, Subramaniam S, Hakonarson H, Sindhi R.

Sci Rep. 2016 Dec 2;6:38347. doi: 10.1038/srep38347.

13.

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.

Jiang L, Huang J, Higgs BW, Hu Z, Xiao Z, Yao X, Conley S, Zhong H, Liu Z, Brohawn P, Shen D, Wu S, Ge X, Jiang Y, Zhao Y, Lou Y, Morehouse C, Zhu W, Sebastian Y, Czapiga M, Oganesyan V, Fu H, Niu Y, Zhang W, Streicher K, Tice D, Zhao H, Zhu M, Xu L, Herbst R, Su X, Gu Y, Li S, Huang L, Gu J, Han B, Jallal B, Shen H, Yao Y.

PLoS Genet. 2016 Apr 19;12(4):e1005895. doi: 10.1371/journal.pgen.1005895. eCollection 2016 Apr.

14.

Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children.

Ashokkumar C, Soltys K, Mazariegos G, Bond G, Higgs BW, Ningappa M, Sun Q, Brown A, White J, Levy S, Fazzolare T, Remaley L, Dirling K, Harris P, Hartle T, Kachmar P, Nicely M, OʼToole L, Boehm B, Jativa N, Stanley P, Jaffe R, Ranganathan S, Zeevi A, Sindhi R.

Transplantation. 2017 Jan;101(1):131-140. doi: 10.1097/TP.0000000000001076.

15.

Profile of the Pleximmune blood test for transplant rejection risk prediction.

Sindhi R, Ashokkumar C, Higgs BW, Levy S, Soltys K, Bond G, Mazariegos G, Ranganathan S, Zeevi A.

Expert Rev Mol Diagn. 2016;16(4):387-93. doi: 10.1586/14737159.2016.1139455. Epub 2016 Feb 16.

16.

Enhanced B Cell Alloantigen Presentation and Its Epigenetic Dysregulation in Liver Transplant Rejection.

Ningappa M, Ashokkumar C, Higgs BW, Sun Q, Jaffe R, Mazariegos G, Li D, Weeks DE, Subramaniam S, Ferrell R, Hakonarson H, Sindhi R.

Am J Transplant. 2016 Feb;16(2):497-508. doi: 10.1111/ajt.13509. Epub 2015 Dec 11.

17.

HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.

Xue F, Higgs BW, Huang J, Morehouse C, Zhu W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, Xia Y, Shen D, Kuziora M, Dong Z, Han H, Gu Y, Gu J, Xia Q, Yao Y.

J Transl Med. 2015 Dec 11;13:379. doi: 10.1186/s12967-015-0743-2.

18.

A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality.

Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, Yao Y, Valge-Archer V, Hammond SA, Dieu-Nosjean MC, Higgs BW.

Oncoimmunology. 2015 Jun 1;4(12):e1051922. eCollection 2015 Dec.

19.

BubbleTree: an intuitive visualization to elucidate tumoral aneuploidy and clonality using next generation sequencing data.

Zhu W, Kuziora M, Creasy T, Lai Z, Morehouse C, Guo X, Sebastian Y, Shen D, Huang J, Dry JR, Xue F, Jiang L, Yao Y, Higgs BW.

Nucleic Acids Res. 2016 Feb 29;44(4):e38. doi: 10.1093/nar/gkv1102. Epub 2015 Nov 17.

20.

In Vivo Therapeutic Success of MicroRNA-155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage.

Zhou S, Wang Y, Meng Y, Xiao C, Liu Z, Brohawn P, Higgs BW, Jallal B, Jia Q, Qu B, Huang X, Tang Y, Yao Y, Harley JB, Shen N.

Arthritis Rheumatol. 2016 Apr;68(4):953-64. doi: 10.1002/art.39485.

21.

The Role of ARF6 in Biliary Atresia.

Ningappa M, So J, Glessner J, Ashokkumar C, Ranganathan S, Min J, Higgs BW, Sun Q, Haberman K, Schmitt L, Vilarinho S, Mistry PK, Vockley G, Dhawan A, Gittes GK, Hakonarson H, Jaffe R, Subramaniam S, Shin D, Sindhi R.

PLoS One. 2015 Sep 17;10(9):e0138381. doi: 10.1371/journal.pone.0138381. eCollection 2015.

22.

CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes.

Roberts MEP, Higgs BW, Brohawn P, Pilataxi F, Guo X, Kuziora M, Bowler RP, White WI.

Chronic Obstr Pulm Dis. 2015 Aug 23;2(4):268-280. doi: 10.15326/jcopdf.2.4.2015.0131.

23.

In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors.

Pore N, Jalla S, Liu Z, Higgs B, Sorio C, Scarpa A, Hollingsworth R, Tice DA, Michelotti E.

Neoplasia. 2015 Jun;17(6):473-80. doi: 10.1016/j.neo.2015.05.001.

24.

Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Guo X, Higgs BW, Bay-Jensen AC, Karsdal MA, Yao Y, Roskos LK, White WI.

J Invest Dermatol. 2015 Oct;135(10):2402-2409. doi: 10.1038/jid.2015.188. Epub 2015 May 20.

25.

Genome-wide association studies in biliary atresia.

Ningappa M, Min J, Higgs BW, Ashokkumar C, Ranganathan S, Sindhi R.

Wiley Interdiscip Rev Syst Biol Med. 2015 Sep-Oct;7(5):267-73. doi: 10.1002/wsbm.1303. Epub 2015 May 11. Review.

PMID:
25963027
26.

Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations.

Jin G, Zhu M, Yin R, Shen W, Liu J, Sun J, Wang C, Dai J, Ma H, Wu C, Yin Z, Huang J, Higgs BW, Xu L, Yao Y, Christiani DC, Amos CI, Hu Z, Zhou B, Shi Y, Lin D, Shen H.

Am J Hum Genet. 2015 May 7;96(5):832-40. doi: 10.1016/j.ajhg.2015.03.009. Epub 2015 Apr 30.

27.

Antithymocyte globulin facilitates alloreactive T-cell apoptosis by means of caspase-3: potential implications for monitoring rejection-free outcomes.

Ashokkumar C, Sun Q, Ningappa M, Higgs BW, Mazariegos G, Zeevi A, Sindhi R.

Transplantation. 2015 Jan;99(1):164-70. doi: 10.1097/TP.0000000000000289.

28.

Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.

Sungalee S, Mamessier E, Morgado E, Grégoire E, Brohawn PZ, Morehouse CA, Jouve N, Monvoisin C, Menard C, Debroas G, Faroudi M, Mechin V, Navarro JM, Drevet C, Eberle FC, Chasson L, Baudimont F, Mancini SJ, Tellier J, Picquenot JM, Kelly R, Vineis P, Ruminy P, Chetaille B, Jaffe ES, Schiff C, Hardwigsen J, Tice DA, Higgs BW, Tarte K, Nadel B, Roulland S.

J Clin Invest. 2014 Dec;124(12):5337-51. doi: 10.1172/JCI72415. Epub 2014 Nov 10.

29.

The transcription factor, T-bet, primes intestine transplantation rejection and is associated with disrupted mucosal homeostasis.

Ranganathan S, Ashokkumar C, Ningappa M, Schmitt L, Higgs BW, Sindhi R.

Transplantation. 2015 Apr;99(4):890-4. doi: 10.1097/TP.0000000000000445.

PMID:
25340608
30.

Comparison of effective I-131 half-life between thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone for thyroid cancer: a retrospective study.

Grenfell S, Roos D, Rijken J, Higgs B, Kirkwood I.

J Med Imaging Radiat Oncol. 2015 Apr;59(2):248-54. doi: 10.1111/1754-9485.12238. Epub 2014 Oct 6.

PMID:
25287576
31.

The functional range of motion of the finger joints.

Bain GI, Polites N, Higgs BG, Heptinstall RJ, McGrath AM.

J Hand Surg Eur Vol. 2015 May;40(4):406-11. doi: 10.1177/1753193414533754. Epub 2014 May 23.

PMID:
24859993
32.

Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies.

Georgantas RW, Streicher K, Greenberg SA, Greenlees LM, Zhu W, Brohawn PZ, Higgs BW, Czapiga M, Morehouse CA, Amato A, Richman L, Jallal B, Yao Y, Ranade K.

Arthritis Rheumatol. 2014 Apr;66(4):1022-33. doi: 10.1002/art.38292.

33.

Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma.

Jiang L, Zhu W, Streicher K, Morehouse C, Brohawn P, Ge X, Dong Z, Yin X, Zhu G, Gu Y, Ranade K, Higgs BW, Yao Y, Huang J.

BMC Cancer. 2014 Feb 26;14:131. doi: 10.1186/1471-2407-14-131.

34.

The plasma cell signature in autoimmune disease.

Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, Brohawn PZ, Higgs BW, McKeever K, Greenberg SA, Fiorentino D, Richman LK, Jallal B, Herbst R, Yao Y, Ranade K.

Arthritis Rheumatol. 2014 Jan;66(1):173-84. doi: 10.1002/art.38194.

35.

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.

Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, Roskos LK, White WI.

Rheumatology (Oxford). 2014 Apr;53(4):686-95. doi: 10.1093/rheumatology/ket413. Epub 2013 Dec 19.

36.

MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.

Georgantas RW 3rd, Streicher K, Luo X, Greenlees L, Zhu W, Liu Z, Brohawn P, Morehouse C, Higgs BW, Richman L, Jallal B, Yao Y, Ranade K.

Pigment Cell Melanoma Res. 2014 Mar;27(2):275-86. doi: 10.1111/pcmr.12200. Epub 2014 Jan 17.

PMID:
24289491
37.

Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.

Jiang L, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y.

Cancer Genet. 2013 Sep-Oct;206(9-10):330-9. doi: 10.1016/j.cancergen.2013.09.004. Epub 2013 Oct 2.

38.

Molecular profiling to diagnose a case of atypical dermatomyositis.

Sarin KY, Chung L, Kim J, Higgs BW, Jallal B, Yao Y, Fiorentino DF.

J Invest Dermatol. 2013 Dec;133(12):2796-2799. doi: 10.1038/jid.2013.240. Epub 2013 Jun 3. No abstract available.

39.

Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody.

Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, Liang M, White WI, Yoo S, Richman L, Jallal B, Roskos L, Yao Y.

Clin Pharmacol Ther. 2013 Jun;93(6):483-92. doi: 10.1038/clpt.2013.35. Epub 2013 Feb 14.

PMID:
23511714
40.

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, Rebelatto M, Le C, Amato A, Fiorentino D, Greenberg SA, Drappa J, Richman L, Greth W, Jallal B, Yao Y.

Ann Rheum Dis. 2014 Jan;73(1):256-62. doi: 10.1136/annrheumdis-2012-202794. Epub 2013 Feb 23.

41.

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W.

Arthritis Rheum. 2013 Apr;65(4):1011-21. doi: 10.1002/art.37824.

42.

Mucosal plasma cell barrier disruption during intestine transplant rejection.

Ningappa M, Ashokkumar C, Ranganathan S, Schmitt L, Higgs BW, Sun Q, Branca M, Mazariegos G, Zeevi A, Abu-Elmagd K, Squires R, Rudolph J, Alissa F, Hakonarson H, Sindhi R.

Transplantation. 2012 Dec 27;94(12):1236-42. doi: 10.1097/TP.0b013e3182708d9d.

PMID:
23269450
43.

Genomic signatures characterize leukocyte infiltration in myositis muscles.

Zhu W, Streicher K, Shen N, Higgs BW, Morehouse C, Greenlees L, Amato AA, Ranade K, Richman L, Fiorentino D, Jallal B, Greenberg SA, Yao Y.

BMC Med Genomics. 2012 Nov 21;5:53. doi: 10.1186/1755-8794-5-53.

44.

Expression profiles of mitochondrial genes in the frontal cortex and the caudate nucleus of developing humans and mice selectively bred for high and low fear.

Choi KH, Le T, McGuire J, Coyner J, Higgs BW, Diglisic S, Johnson LR, Benedek DM, Ursano RJ.

PLoS One. 2012;7(11):e49183. doi: 10.1371/journal.pone.0049183. Epub 2012 Nov 13.

45.

Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus.

Fan W, Liang D, Tang Y, Qu B, Cui H, Luo X, Huang X, Chen S, Higgs BW, Jallal B, Yao Y, Harley JB, Shen N.

Arthritis Rheum. 2012 Nov;64(11):3715-25. doi: 10.1002/art.34596.

46.

Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.

Higgs BW, Zhu W, Richman L, Fiorentino DF, Greenberg SA, Jallal B, Yao Y.

Int J Rheum Dis. 2012 Feb;15(1):25-35. doi: 10.1111/j.1756-185X.2011.01654.x. Epub 2011 Aug 31.

PMID:
22324944
47.

Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases.

Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, Yao Y, Fiorentino D.

PLoS One. 2012;7(1):e29161. doi: 10.1371/journal.pone.0029161. Epub 2012 Jan 3.

48.

CallSim: Evaluation of Base Calls Using Sequencing Simulation.

Morrow JD, Higgs BW.

ISRN Bioinform. 2012 Dec 12;2012:371718. doi: 10.5402/2012/371718. eCollection 2012.

49.

Allospecific CD154 + T-cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantation.

Sindhi R, Ashokkumar C, Higgs BW, Gilbert PB, Sun Q, Ranganathan S, Jaffe R, Snyder S, Ningappa M, Soltys KA, Bond GJ, Mazariegos GV, Abu-Elmagd K, Zeevi A.

Pediatr Transplant. 2012 Feb;16(1):83-91. doi: 10.1111/j.1399-3046.2011.01617.x. Epub 2011 Nov 29. Erratum in: Pediatr Transplant. 2012 Dec;16(8):913.

PMID:
22122074
50.

Altered expression of insulin receptor isoforms in breast cancer.

Huang J, Morehouse C, Streicher K, Higgs BW, Gao J, Czapiga M, Boutrin A, Zhu W, Brohawn P, Chang Y, Viner J, LaVallee T, Richman L, Jallal B, Yao Y.

PLoS One. 2011;6(10):e26177. doi: 10.1371/journal.pone.0026177. Epub 2011 Oct 26.

Supplemental Content

Support Center